Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix Reports Q2 2018 Financial Results
Initial $3.8M Milestone Achieved under GSK Strategic Collaboration WALTHAM, Mass. , July 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported financial and business highlights for the quarter ended June 30, 2018 . The Company develops and markets novel therapies, based on
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for 2018 Second Quarter Financial Results Conference Call
WALTHAM, Mass. , July 12, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ:NURO) announced today that it plans to issue its 2018 second quarter financial results before the opening of the market on Thursday, July 19, 2018. The Company will host a conference call at 8:00 a.m., Eastern
View HTML
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for DPNCheck Point-of-Care Neuropathy Test Technology
WALTHAM, Mass. , July 05, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,004,445. The patent covers novel technology that enhances DPNCheck ® device performance by detecting and rejecting erroneous
View HTML
Toggle Summary NeuroMetrix PR Campaign Wins Gold at the Publicity Club of New England 2018 Bell Ringer Awards
“Moving Beyond Opioids: How Technological Innovations Can Impact Chronic Pain” earns top award in healthcare publicity campaign category WALTHAM, Mass. , June 28, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) in conjunction with its public relations firm, InkHouse, received two
View HTML
Toggle Summary NeuroMetrix Reports Publication of New Clinical Studies on DPNCheck
WALTHAM, Mass. , June 26, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported publication of three new clinical studies on DPNCheck ® , a point-of-care device that provides accurate and cost-effective screening, diagnosis, and monitoring of diabetic peripheral neuropathy (DPN).
View HTML
Toggle Summary NeuroMetrix Report Highlights Stigma Faced by Chronic Pain Community around Opioid Use, Desire for Alternative Treatments
84 percent of Americans living with chronic pain believe there is a stigma around opioid use; 90 percent are actively seeking alternative treatments WALTHAM, Mass. , June 21, 2018 (GLOBE NEWSWIRE) -- The opioid crisis continues to make headlines, but in the midst of this chaos, members of the
View HTML
Toggle Summary NeuroMetrix Receives $3.8M Milestone Payment Under Its Collaboration with GSK Consumer Healthcare
WALTHAM, Mass. , June 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported that it had achieved the first development milestone under its strategic collaboration with GSK Consumer Healthcare . A milestone payment of $3.8 Million was made by GSK.
View HTML
Toggle Summary Preliminary Results from Quell Chronic Low Back Pain Study to be Presented at World Institute of Pain World Congress
WALTHAM, Mass. , May 03, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported that preliminary results from a study of Quell ® wearable pain relief in chronic low back pain will be presented at the 9th World Congress of the World Institute of Pain in Dublin, Ireland May 9-12,
View HTML
Toggle Summary NeuroMetrix, Inc. to Participate in Upcoming Disruptive Growth & Healthcare Conference in New York City
WALTHAM, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), announced today that it will be participating in the 3rd annual Disruptive Growth & Healthcare Conference in New York City on May 8-9, 2018 sponsored by RHK Capital and ReedSmith.
View HTML
Toggle Summary NeuroMetrix to Present Quell Data at Upcoming American Academy of Pain Medicine Annual Meeting
WALTHAM, Mass. , April 24, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it will present two scientific posters at the upcoming 2018 American Academy of Pain Medicine (AAPM) Annual Meeting to be held in Vancouver, Canada , April 26-28 .
View HTML